Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Melbourn Scientific Announces First Nasal Device Testing Lab at ICSE

Published: Thursday, September 20, 2012
Last Updated: Wednesday, September 19, 2012
Bookmark and Share
Service offers GMP analysis of droplet size, particle characterization, spray pattern and plume geometry.

The multiple benefits of a nasal spray has triggered a boom in product development activity generating greater demand for Melbourn Scientific’s expertise in formulation analysis and performance testing.

In response the company has created a dedicated laboratory to provide GMP testing of nasal device performance, the first in Europe to offer such a comprehensive service.

Mark Hammond, CEO of Melbourn Scientific says: “We predicted a few years ago that nasal delivery of compounds would increase as companies realized the benefits of this route. A nasal device offers a user friendly, painless, non-invasive route for drug administration.

“We are now seeing evidence of continued growth and that clients recognize the advantages of working with partners that have expertise in this area of drug delivery and understand the formulation and analytical challenges that it brings.

The portfolio of nasal spray services offered by Melbourn includes: nasal device performance testing, droplet size and distribution analysis, spray pattern and plume geometry analysis.

The new laboratory was included within a recent FDA inspection, which the company passed with ‘no significant deficiencies noted and no 483s issued’.

“The high surface area in the nasal cavity provides drugs with direct access to the systemic circulation providing rapid onset of action. This route also avoids any degradation from first pass metabolism, which means lower doses can be given reducing the possibility of unwanted side effects.”

The nasal cavity has a large surface area and high permeability, and the location of lymphoid tissue at the back of the nasal cavity offers rapid transport into the systemic circulation.

The olfactory region at the top of the nasal cavity is of interest for the treatment for age-associated diseases such as Alzheimer’s, as it allows rapid absorption into the central nervous system.

The nasal route can also enhance performance for a wide range of treatments from the instant relief of panic attacks through to needle-free vaccinations.

However, the challenge of a nasal delivery device is to get the particle size right in order to ensure that the drug is deposited within the nasal passages and not the lungs or gastro-intestinal tract. This is where a comprehensive testing regime is beneficial.

Mark explains, “Depending upon the drug and device properties there are a number of considerations for the formulation, here at Melbourn Scientific we have developed a range of screening tools to enable us to fast track formulation development of the product from simple solutions, through suspensions to dry powder blends using a wide range of excipients.

“Our formulation development is supported by standalone testing services with significant investment in specialist equipment. The new lab will make this available as a comprehensive service.”

Equipment includes: the Malvern Spraytec, which is designed to capture information about both pulsed spray and continuous spray events, Morphologi G3 an optical imaging tool that provides more information about individual particles giving data about their size, shape and solidity and the new Proveris’s SprayVIEW, a FDA accepted spray pattern and plume geometry analysis service.

Melbourn Scientific has also appointed a new business development executive Liz Parkhouse to provide a point of contact for the nasal spray testing service. She will be at ICSE to talk to visitors.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!